OBJECTIVE: Chronic hypertension is a common medical condition in pregnancy. The purpose of the study was to examine the association between maternal chronic hypertension and the risk of congenital malformations in the offspring.
C hronic hypertension is a common medical condition in pregnancy, and its prevalence is rising because a larger number of parturients are obese and of advanced maternal age. 1, 2 As a consequence, exposure to antihypertensive medications during pregnancy, including in the first trimester when organogenesis occurs, is common and increasing. [3] [4] [5] Certain classes of antihypertensive medications taken during the first trimester including beta blockers, diuretics, and angiotensin-converting enzyme inhibitors have been associated with an increased risk of specific congenital malformations. [6] [7] [8] [9] [10] [11] However, several recent studies have suggested that it may be the underlying chronic hypertension that confers risk and not exposure to these medications per se, because of the following: (1) an elevation in risk of malformations was observed across antihypertensive classes and/or (2) the association with certain medications was no longer present when medication users were compared with a control group that included untreated hypertensive patients. 6, 8, 12 Little is known about the role of chronic hypertension alone in conferring a risk of congenital malformations, and there has been a call from experts for further study in this area. 13 Specifically, there are few data on whether chronic hypertension confers a risk of malformations independent of other confounding factors (eg, diabetes, maternal age, antihypertensive agents) and which specific malformations, if any, are associated with hypertension. Such information may be useful to clinicians in counseling patients and in guiding screening for malformations.
It may also be important in informing the design of future studies of the teratogenic potential of antihypertensive medications. We therefore sought to examine the effect of chronic hypertension on the risk of congenital malformations in a large cohort of pregnancies in Medicaid beneficiaries.
MATERIALS AND METHODS

Cohort
The cohort was derived from the Medicaid Analytic eXtract (MAX), which contains information on Medicaid beneficiaries; Medicaid is the joint state and federal health insurance program for low-income individuals in the United States.
MAX is a health care utilization database that records Medicaid enrollment and utilization claims, including those for inpatient admissions and outpatient visits as well as outpatient pharmacy dispensing claims. Using the MAX data from 2000 to 2007, a cohort was created for the study of drug utilization and safety in pregnancy, as previously described in detail. 14 The use of this database for research was approved by the Partners' Institutional Review Board (Boston, MA). Women with a claim indicating delivery were linked to infants within states using the Medicaid case number (which is generally shared by families) and the infant's date of birth. The woman's last menstrual period (LMP) was assigned using a validated algorithm based on diagnostic codes in the maternal and infant records. 15 We restricted the cohort to women who were eligible for Medicaid continuously from 3 months prior to the estimated LMP month through 1 month postpartum. To ensure complete ascertainment of relevant claims, we restricted our analysis to women with 28 days or more of enrollment each month and without restricted benefits, private insurance, or certain state-specific managed care programs (that underreport claims to MAX).
To allow for an accurate capture of congenital malformations, we also required that the linked infants met the same Medicaid eligibility criteria as the mothers for at least 3 months following the birth (unless they died, in which case a shorter eligibility period was allowed). The source cohort included 891,699 completed pregnancies with linked infants.
We excluded women who were exposed to known teratogenic medications including lithium, antineoplastic agents, retinoids, or thalidomide from the estimated LMP through the date of delivery based on claims for dispensed medications or who had an infant with an inpatient or outpatient diagnosis code indicating the presence of a chromosomal abnormality.
We also excluded women who were exposed to antihypertensive medications during the first trimester but who lacked diagnosis codes indicating chronic hypertension because of a significant risk of misclassifying the presence or absence of hypertension in these patients (because the women may have received the medications for other indications, for example, beta blockers for migraine prophylaxis, or have hypertension that was not properly coded). The final analytic cohort included 878,126 pregnancies ( Figure 1 ).
Exposure
The following 3 groups of women were considered in the analysis: (1) women without chronic hypertension who did not receive antihypertensive medications in the first trimester, (2) women with chronic hypertension who were treated with an antihypertensive medication during the first trimester, and (3) women with chronic hypertension who were not treated with an antihypertensive medication during the first trimester.
Chronic hypertension was defined by codes recorded on 2 or more distinct dates indicating chronic or preexisting hypertension recorded in the maternal inpatient or outpatient record at any time from 3 months prior to the LMP through delivery. The codes were derived from the International Classification of Disease-Clinical Modification, ninth edition, and included codes 642.0x, 642.1x, 642.2x, 642.7x, and 401.xx through 405.xx. These codes are specific to chronic hypertension and are distinct from codes that indicate other hypertensive disorders of pregnancy including gestational hypertension and preeclampsia.
Antihypertensive exposure during the first trimester was defined by a filled prescription whose days' supply overlapped the period from the LMP to 90 days after the LMP. In defining this exposure, we used prescriptions filled from 3 months prior to the LMP until 90 days after the LMP. Duration of exposure was estimated based on the number of days' supply. We accumulated days' supply for consecutive prescriptions of the same medication if the medication was refilled prior to the day that the prior prescription was expected to run out. The list of antihypertensive medications considered in the analysis can be found in the Appendix (Supplementary Table 1 ).
Outcomes
The primary outcome was defined as the presence of a major congenital malformation in the offspring. Major congenital malformations were defined based on having codes on 2 or more separate days in the infant inpatient or outpatient records during the first 3 months of life indicating an organ-specific class of malformations including central nervous system malformations; eye, ear, neck, and face malformations; cardiac malformations; respiratory malformations; cleft palate or lip; gastrointestinal Research Obstetrics ajog.org malformations; genitourinary malformations; musculoskeletal malformations; or other malformations.
We required 2 codes to define the presence of malformations to exclude cases in which a single mention may be recorded to justify a diagnostic test to rule out a condition. Our group has previously validated specific cardiac malformations using this approach with medical records; the positive predicted value was greater than 75%. 16 Secondary outcomes included each of the organspecific malformations. Comorbid medical and obstetric conditions were identified by the presence of 1 or more diagnosis codes in the maternal inpatient or outpatient record from 3 months prior to the estimated LMP through delivery. These included preexisting diabetes mellitus, chronic renal disease, obesity, tobacco use, alcohol abuse, and illicit drug use/abuse. Obstetric conditions included multiple gestations and gestational diabetes. Multiparity was defined based on the woman's Medicaid eligibility type; an eligibility classification of adult with dependent children indicated multiparity.
Covariates
Comorbidities and conditions were assessed until delivery because, although the relevant etiological window for exposures leading to the development of congenital malformations is the first trimester, conditions present during the first trimester (chronic hypertension, diabetes, obesity, etc) may not always be coded with fidelity during this relatively brief window. Additionally, conditions that develop later in pregnancy (eg, gestational diabetes) may be markers for risk factors that are present in the first trimester (maternal obesity or hyperglycemia).
The validity of this approach rests on the assumption that the development of a congenital malformation in the infant does not lead to the development or preferential recording of these maternal conditions. Although this is likely a safe assumption for the conditions assessed, we also conducted a sensitivity analysis to ensure that our findings were robust when the window during which exposure and covariates were ascertained was confined to the prepregnancy period and first trimester (see the following text).
Maternal medication exposures assessed included exposure to either insulin or oral hypoglycemic medications from 3 months prior to the LMP through delivery (which may be markers for the presence or severity of maternal preexisting or gestational diabetes). We also identified and considered as a covariate in our analyses exposure to any potentially teratogenic medications during the first trimester including fluconazole, aminoglycosides, folic acid antagonists, methimazole, potassium iodide, tetracycline, danazol, misoprostol, statins, coumadin, and propylthiouracil, which may act as confounders if women with chronic hypertension are exposed to these medications with a frequency that is different from normotensive women.
Finally, we considered measures of health care utilization during the 3 months prior to the LMP through the end of the first trimester, which may be markers for overall health status and thus have a relationship to the risk for birth defects. These included the number of distinct noneantihypertensive prescription and number of physician visits for any reason (both grouped as 0, 1-3, >3).
Statistical analyses
We determined the baseline characteristics of women without chronic 
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Obstetrics Research hypertension who did not receive antihypertensive medications in the first trimester (controls), women with chronic hypertension who were exposed to an antihypertensive medication during the first trimester (treated chronic hypertensives), and women with chronic hypertension who were not treated with an antihypertensive during the first trimester (untreated chronic hypertensives) and summarized them as counts and proportions.
We conducted 2 separate comparisons in our analyses: (1) controls vs subjects treated for chronic hypertension and (2) controls vs untreated chronic hypertensives. In each analysis, we first determined the frequency of and unadjusted odds ratio (OR) and 95% confidence intervals (CIs) for the primary and secondary outcomes.
To account for the differences in the baseline characteristics in the groups that are being compared, we performed propensity score analyses. In the first analysis (comparing controls and subjects treated for hypertension), we used a logistic regression model to estimate the probability of being a subject treated for hypertension (as opposed to a control) based on the maternal demographic characteristics, comorbid medical conditions, obstetric characteristics/conditions, maternal medication exposures, and measures of health care utilization, as defined in previous text, without further selection (this probability is the propensity score).
Controls and treated subjects treated for chronic hypertension were then matched on their propensity score in a fixed 3:1 ratio using a nearest neighbor algorithm with a maximum matching distance of 0.05. The same approach was used for the comparison of controls with subjects untreated for chronic hypertension. In these matched cohorts, we again estimated the odds ratio and 95% CI for the primary and secondary outcomes.
Sensitivity and exploratory analyses
Because diabetes is such a strong risk factor for congenital malformations 17, 18 and the possibility exists that there may be residual confounding, even adjusting for the presence of diabetes (ie, diabetes may be more severe in the hypertensive patients), we repeated our analysis excluding patients with any codes or medications indicating the presence of diabetes.
Specifically, we excluded women who had any diagnosis codes indicating preexisting or gestational diabetes or who had prescriptions for insulin or oral diabetes medications from 3 months prior to the LMP through delivery. The total number of the excluded patients was 88,937.
We then repeated the propensity scoreematched analysis, focusing on the outcomes of overall congenital malformations and cardiac malformations (which were significantly associated with both treated and untreated hypertension in the primary analysis).
We performed a second sensitivity analysis excluding patients with preterm delivery. Preterm delivery has a complex relationship to congenital malformations because of the following: (1) infants with congenital malformations are more likely to deliver preterm, and (2) infants born preterm will sometimes have conditions that might be coded as malformations (eg, patent ductus arterious, patent foramen ovale, undescended testes) that would have spontaneously resolved had the infant been carried to term.
In the first scenario, controlling for prematurity could induce an association between hypertension or antihypertensives and malformations. In the second scenario, controlling for prematurity would be justified if we were interested in the direct effect of hypertension or antihypertensives not mediated through prematurity, assuming our analyses properly adjusted for shared risk factors of malformations and prematurity. 19 In the primary analysis, we assumed the first scenario and did not adjust for preterm delivery. In this sensitivity analysis, we assumed scenario two and condition on prematurity through restriction. The total number of pregnancies excluded in this analysis was 98,049. We again repeated the main analysis for the outcomes of overall congenital malformations and cardiac malformations.
In the primary analysis, we collected information on covariates from prior to the LMP through delivery to improve our ascertainment of chronic hypertension and conditions that might confound the association of chronic hypertension and malformations. However, if a woman is diagnosed as carrying an infant with a malformation on prenatal ultrasound, it is possible that her medical conditions would be scrutinized more carefully and/or recorded more accurately in the medical record (surveillance bias). To ensure that this potential bias did not affect our results, we repeated our analysis defining chronic hypertension and the covariates used in the analysis based solely on codes recorded in the maternal record from 3 months prior to the LMP through the end of the first trimester.
We required codes in the infant record recorded on separate days to define the presence of an organ-specific malformation in the primary analysis. This was done to minimize the risk of identifying malformations based on codes used to justify rule-out diagnostic tests. However, to test that our results were robust to this approach, we repeated the primary analysis with the outcome defined based on 1 or more codes in infant inpatient or outpatient record from day of birth to day 90 of life.
To determine the potential effects of residual confounding in our analyses, we defined the strength (confounderoutcome relative risk) of a hypothetical residual confounder that, if present, would explain the effect of treated and untreated chronic hypertension on the risk of developing a congenital malformation. Because the strength of confounders depends on the relative prevalence, we assumed a prevalence of 5% among the normotensive controls and then a range of prevalences in the treated and untreated chronic hypertension patients (which were analyzed separately). 20 As an exploratory analysis, we repeated the primary analysis, examining the association of treated and untreated hypertension and specific cardiac malformations including ventricular septal defect, right ventricular outflow Analyses were performed in SAS version 9.3 (SAS Institute, Cary, NC).
RESULTS
Our primary cohort consisted of 878,126 completed pregnancies. Overall, 19,789 (2.3%) had chronic hypertension; of these, 8307 (42.0%) were treated with antihypertensive medication. As shown in Table 1 , there were important baseline differences in patients without hypertension, with treated hypertension, and with untreated hypertension.
Patients with chronic hypertension tended to be older, were more often African-American, and had a higher prevalence of preexisting diabetes, gestational diabetes, and renal disease. They were also more often exposed to insulin or other diabetic medications. These differences from normotensive controls were greater for patients with treated chronic hypertension than untreated hypertension. After propensity score matching, these imbalances were no longer present, with the absolute difference in the frequency of all covariates less than 2% (Table 2) .
Congenital malformations in the offspring were observed in 29,934 pregnancies without chronic hypertension or antihypertensive exposure (3.49%), 491 pregnancies with treated chronic hypertension (5.91%), and 581 pregnancies with untreated hypertension (5.06%). The most commonly observed organspecific malformations in the offspring were cardiac, followed by musculoskeletal, genitourinary, and gastrointestinal (Supplementary Table 2 ).
In the unadjusted analyses, compared with controls without chronic hypertension, those with treated chronic hypertension had a higher risk of any congenital malformation (OR, 1.7; 95% CI, 1.6e1.9), as did those with untreated chronic hypertension (OR, 1.5; 95% CI, 1.4e1.6). In the analysis of organspecific malformations, those with treated hypertension had a statistically significantly increased risk of infants affected by central nervous system malformations, cardiac malformations, respiratory malformations, genitourinary malformations, and other malformations (including malformations of the integument and malformations not otherwise specified) compared with controls.
Women with untreated hypertension had a significantly higher risk of cardiac malformations and genitourinary malformations in their offspring compared with controls without chronic hypertension (Table 3) . Point estimates for several other malformations were also increased in the treated and untreated hypertension groups, albeit with CIs that intersected the null.
In the propensity scoreematched analysis, there was a higher risk of composite congenital malformations in the infants of both women with treated chronic hypertension (OR, 1.3; 95% CI, 1.2e1.5) and untreated chronic hypertension (OR, 1.2; 95% CI, 1.1e1.3) compared with normotensive controls. In the analysis of organ-specific malformations, in the propensity score matched analyses, both treated and Values are numbers (percentages). Also included as covariates are the following: multiple births, muliparity, obesity, alcohol abuse, illicit drug use, potentially teratogenic medications during first trimester, distinct noneantihypertensive prescriptions drugs from 90 days before to 90 days after the LMP, number of physician visits for any reason from 90 days before to 90 days after the LMP, year, and region.
DM, diabetes mellitus; LMP, last menstrual period.
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Obstetrics Research untreated chronic hypertension was associated with an increased risk for cardiac malformations (OR, 1.6; 95% CI, 1.4e1.9 and OR, 1.5; 95% CI, 1.3e1.7, respectively) compared with normotensive controls. Point estimates for several other malformations, including central nervous system malformations and respiratory malformations, were increased for women with both treated and untreated chronic hypertension, although CIs for these associations intersected the null (Table 3) .
Across each of the sensitivity analyses, both treated and untreated chronic hypertension was associated with an increased risk of the composite congenital malformation and cardiac malformation endpoints in the offspring, although for some of these associations, the CIs intersected the null (Table 4) . The estimate for the association of untreated chronic hypertension and composite congenital malformations and cardiac malformations was somewhat attenuated when preterm deliveries were excluded.
We defined the strength of a hypothetical residual confounder that could have produced the observed effect of treated chronic hypertension on the risk of overall malformations from the primary analysis (adjusted OR, 1.3) and then repeated this analysis for untreated hypertension (adjusted OR, 1.2). For both analyses we assumed a prevalence of the hypothetical confounder of 5% in the normotensive control group. A confounder-outcome risk ratio of 9.6 would be required to produce the observed effect of treated chronic hypertension if the prevalence of the confounder in the treated hypertension group was 10%, a risk ratio of 3.2 if the prevalence was 20% and a risk ratio of 2.3 if the prevalence was 30%. For the untreated chronic hypertension effect to be explained by an unmeasured confounder, a confounder-outcome risk ratio of 6.6 would be required if the prevalence of the confounder in the untreated hypertension group was 10%, a risk ratio of 2.6 if the prevalence was 20%, and a risk ratio of 1.9 if the prevalence was 30% (Figure 2) .
Having demonstrated an association between cardiac malformations and both treated and untreated hypertension, we explored the association with specific types of cardiac malformations. Point estimates for most malformations examined were modestly increased for both treated and untreated chronic hypertensive patients, although in the setting of small numbers most CIs were wide and intersected the null (Table 4) .
COMMENT
In this cohort of 878,126 pregnancies, we found that both treated and untreated maternal chronic hypertension were associated with a similar 20-30% increase in the risk of congenital malformations in the infant after adjusting for confounding factors as compared with normotensive controls. This increase in risk persisted across a number of sensitivity analyses. In our evaluation of organ-specific malformations, both treated and untreated chronic hypertension was associated with an increased risk of cardiac malformations.
Chronic hypertension has not been traditionally identified as a risk factor for congenital malformations in the offspring. As such, most prior studies of the teratogenic potential of antihypertensive medications have not carefully accounted for potential confounding by indication. Our findings therefore have important implications in informing the way in which the studies of antihypertensive drug safety in pregnancy should be performed going forward. These findings also identify congenital malformations as an important complication associated with chronic hypertension, which may have clinical implications for antenatal screening in affected women.
There are few studies that have explored the role of hypertension in conferring risk of congenital malformations in the offspring. A cohort study by Li et al 12 of the teratogenic potential of angiotensinconverting enzyme inhibitors in the first trimester found that a comparison group of patients with untreated hypertension, as defined by diagnosis codes indicating hypertension from prior to pregnancy through delivery, had an increased risk of congenital heart defects and neural tube defects. Caton et al, 6 in a case-control study, found that untreated hypertension (again, defined by hypertension anytime during pregnancy) was associated with an increased point estimate for cardiovascular malformations but with wide CIs that intersected the null.
Our findings confirm and extend these observations from previous studies. First, we examined the role specifically of chronic hypertension in conferring the risk of malformations, whereas prior studies examined all pregnancy-related hypertensive disorders together. 6, 12 Chronic hypertension is the most etiologically relevant type of hypertension to examine because, in contrast to other hypertensive disorders of pregnancy such as gestational hypertension or preeclampsia, it is present in the first trimester (the period during which organogenesis occurs). Odds ratios and 95% confidence intervals are shown.
PS, propensity score.
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Second, our study examined a full range of organ-specific congenital malformations in relation to hypertension, finding that chronic hypertension is associated most strongly with cardiac malformations.
Third, our study carefully controlled for a wide range of potential confounders of the association between chronic hypertension and congenital malformations including comorbid conditions as well as other relevant medication exposures and markers of overall health status and health care utilization.
Finally, the large size of our cohort allowed us to make relatively precise estimates with regard to the risk of malformations associated with treated and untreated hypertension.
The association between chronic hypertension and malformations may be biologically plausible. Chronic hypertension can result in uteroplacental insufficiency that accounts, at least in part, for its association with intrauterine growth restriction, intrauterine fetal demise, and superimposed preeclampsia.
2,21-25 Uteroplacental insufficiency can lead to compromised blood flow to the developing fetus, which, if present in early pregnancy, may, in turn, increase the risk for certain types of malformations, particularly cardiovascular malformations 6, 26 ; previous authors have postulated that this mechanism may explain the link between hypertension and cardiac malformations. 6 That being said, much remains to be learned about the biological mechanisms that explain the observed association between chronic hypertension and malformations and whether controlling hypertension would reduce the risk. Our results, coupled with the rapidly rising prevalence of chronic hypertension in pregnancy, motivate such work. 1, 2 Our findings also significantly inform the interpretation of prior studies examining the teratogenic potential of antihypertensive medications. [6] [7] [8] [9] [10] [11] Studies that identify an association of these medications with malformations but Odds ratios and 95% confidence intervals shown.
DM, diabetes mellitus; GDM, gestational diabetes mellitus; PS, propensity score.
Research Obstetrics ajog.org that do not control for potential confounding by indication must be interpreted with caution. Future studies examining the role of specific antihypertensive medications will need to carefully choose a comparator group of patients with the same underlying condition to yield valid results.
The results of the study may inform the performance of antenatal screening tests. Guideline groups have advocated for the use of fetal echocardiography based on maternal comorbidities that confer increased risk of congenital cardiac malformations. 27 The crude risks observed in our study suggest that women with chronic hypertension have a 50-70% greater risk of cardiac malformations compared with normotensive controls (which attenuated to 20-30% after controlling for confounders), suggesting that this group may benefit from such testing. Future work will need to establish the clinical benefits and cost-effectiveness of performing fetal echocardiography in this population.
Our results should be interpreted in the context of limitations inherent in its design. Although the MAX database contains detailed information on patient demographics, outpatient medication utilization, and inpatient and outpatient diagnoses, it is health care utilization data that are not collected primarily for research purposes and thus lack some relevant clinical details. For example, the patients' blood pressures are not directly recorded in the MAX, and thus, we are reliant on physicians' diagnosis of chronic hypertension in defining exposure. Likewise, the database does not contain detailed information describing the malformations diagnosed in the infants and the definition of malformations is confined to those identified in early infancy.
To overcome these potential limitations, we defined the presence of both the chronic hypertension and the outcome of malformations based on 2 instances of coding in the maternal or infant record, respectively, meaning that a physician diagnosed these conditions on 2 separate occasions. Such an approach is expected to define both exposure and outcome with high specificity. When the outcome is defined with high specificity (even in the presence of limited sensitivity), results from an observational study will yield unbiased estimates of the relative risk of the association of the exposure with the outcome. 28 Furthermore, any misclassification of the outcome in the study would be expected to be nondifferential in the groups compared. As a consequence, if the misclassification of outcome is present in our study, estimates of the association between chronic hypertension and malformations would, if anything, be biased to the null.
In studying the association between a chronic maternal condition and malformations, there is the possibility that the findings may be subject to ascertainment bias if the infants of women with the condition are examined for malformations more carefully than those of unaffected women; however, this bias is unlikely to be playing a major role in the findings of the present study because chronic hypertension has not traditionally been thought in the malformation to be a risk factor for malformations as well as the fact that many of the specific cardiac malformations associated with hypertension (Table 4) present a threat to the life of the infant and/or require surgical intervention.
The timing of the LMP is not recorded directly in the database but has to be estimated using an algorithm based on diagnostic codes. Although the algorithm has been demonstrated to perform well in claims data, misclassification of the LMP in some patients is possible. This would not affect the identification of patients with chronic hypertension, but it may lead to some small degree of misclassification of patients' treatment status.
Additionally, although we follow up infants for 90 days after birth when the majority of major malformations are likely to be detected, it is possible that some defects will be detected only later in infancy, leading us to underestimate the prevalence of malformations in the cohort. Furthermore, our ajog.org Obstetrics Research study was conducted in a population of low-income Medicaid beneficiaries. Although the observed effect of chronic hypertension on the risk of malformations is very likely to be generalizable to other populations, even if this were not the case, the results would be of interest, given the large proportion of births in the United States covered by Medicaid.
Finally, we use propensity score matching to control for confounders in our analysis. The estimates of the effect of treated and untreated hypertension on the risks of malformation should be interpreted as generalizable to populations with characteristics of the matched populations, as shown in Table 2 .
Although we were careful to identify potential confounders of the association between chronic hypertension and malformations using maternal inpatient and outpatient diagnostic claims, medications, and health care utilization variables, it remains possible that residual bias is present because of unmeasured or unknown confounders. Our analysis of the potential effect of a hypothetical confounder suggests that for an unobserved confounder to explain our results, it would need to have a strong association with the outcome and be highly prevalent in the exposed group.
Whereas the presence of a single highly prevalent unmeasured confounder of strong effect is unlikely, given our longitudinal assessment of all women in the cohort from 3 months prior to the LMP through delivery, it cannot be excluded that several unmeasured or not perfectly measured confounders might together significantly attenuate the observed associations. For example, although we accounted for confounding by diabetes (both gestational and preexisting) through the use of both diagnosis codes and treatment with insulin or oral diabetes medications, impaired glucose tolerance, which does not meet the threshold for the diagnosis of preexisting or gestational diabetes, may be more common in women with chronic hypertension and thus represent a source of residual confounding.
Our data source also has imperfect data on overweight and obesity, which may represent another source of potential residual confounding. Future work using other data sources will thus be needed to confirm these results. That said, the implications of our results for the design of drug safety studies in pregnancy (need to control for confounding by indication because the confounders measured in our data set are typical of those available in data sets used to study drug safety) and for clinical practice (need for close screening for malformation in women with hypertension) remain, whether or not the observed association is strictly causal.
Our study also cannot directly address whether treatment of chronic hypertension in pregnancy will decrease the risk of malformations. However, if the mechanism underlying the association of chronic hypertension and malformations is, in fact, uteroplacental insufficiency, it is unlikely that treatment will be effective in doing so.
The risks of preeclampsia and small for gestational age associated with chronic hypertension, which may also be secondary to uteroplacental insufficiency, are not decreased through the use of antihypertensive therapy. 29 Likewise, although the estimate of risk of malformations was similar for both treated and untreated chronic hypertension, our study cannot exclude the possibility that certain antihypertensives are teratogenic. Future studies will need to focus on evaluating the safety of particular antihypertensives while carefully accounting for the confounders that are important to those agents.
Our findings suggest that chronic hypertension, whether treated or untreated, has an independent association with the development of major congenital malformations (particularly cardiac malformations). As in all observational studies, we cannot exclude the possibility of residual confounding and additional studies replicating these findings are necessary before chronic hypertension should be considered an established risk factor for congenital malformations.
Future research is also needed to define the biological basis for this association and to determine how it might be modified. Studies of the teratogenic potential of antihypertensive medications in pregnancy need to be attentive to confounding by indication. Clinically, the findings suggest that hypertensive women may benefit from more intensive screening for cardiac malformations in the fetus/neonate.
SUPPLEMENTARY TABLE 2
Offspring with composite and organ-specific malformations in both the overall cohort and the propensity-score matched cohorts 
